The LKB1-AMPK pathway-friend or foe in cancer?

Cancer cell ·Vol. 23 ·No. 2 ·2013-02-11 ·Pages 131-2

Hardie DG

Abstract

Use of the biguanide metformin, an AMPK activator, is associated with a reduced incidence of cancer in diabetics, but it has been unclear whether this requires AMPK. In this issue of Cancer Cell, Shackelford and colleagues show, paradoxically, that biguanides are more effective in the treatment of mouse tumors that lack a functional LKB1-AMPK pathway.

Authors & Affiliations

1 authors, click to expand affiliations / ORCID

Hardie D Grahame

Division of Cell Signalling and Immunology, College of Life Sciences, University of Dundee, Dundee DD1 5EH, Scotland, UK. d.g.hardie@dundee.ac.uk

Article Info

Journal

Cancer cell

Abbr.

Cancer Cell

ISSN

1878-3686

DOI

10.1016/j.ccr.2013.01.009

d.g.hardie@dundee.ac.uk

Published

2013-02-11

Pages

131-2

Language

English

Region

United States

NLM ID

101130617

Grants

Wellcome Trust · 097726 · United Kingdom

Corrections

CommentOn

PMID: 23352126

External Links

PubMed source DOI: 10.1016/j.ccr.2013.01.009 View journal details

Analysis Services

The LKB1-AMPK pathway-friend or foe in cancer?

Contact

WeChat Official Account